IMMUNO-ONCOLOGY INSIGHTS

Clinical development strategy

Guest Editor:
Jon Wigginton, Chief Medical Officer, Cullinan Oncology
Jon Wigginton
Chief Medical Officer, Cullinan Oncology
Jon Wigginton, MD currently serves as portfolio Chief Medical Officer, Cullinan Oncology and Advisor at MPM Capital. Dr. Wigginton most recently served as the Chief Medical Officer at MacroGenics, where he led the company's evolution of a fully-integrated, clinical-stage cancer immunotherapy organization. Previously, he served as the Therapeutic Area Head, Immuno-Oncology, Early Clinical Research at Bristol-Myers Squibb. There, he oversaw early clinical development of the BMS Immuno-Oncology portfolio, served in governance role for discovery research, and co-led the BMS International Immuno-Oncology Network (II-ON). These efforts included several studies defining proof-of concept for both anti-PD-1 and anti-PD-L1 antibodies in patients with a variety of solid tumors, and for the anti-PD-1/anti-CTLA-4 combination in patients with melanoma. During his academic career, Dr. Wigginton served as Head of the Investigational Biologics Section, Center for Cancer Research, NCI, where he led an integrated basic, translational and clinical research effort focused on combination immunotherapy in preclinical models and early clinical studies. Dr. Wigginton also served previously as president of the Society for Immunotherapy of Cancer (SITC). Dr. Wigginton received his M.D. and B.S. in Biology, with distinction, from the University of Michigan.
October 2020

  • Immuno-Oncology Insights - Spotlight on clinical development strategy

    Immuno-Oncology Insights - Spotlight on clinical development strategy

    9 September 2020
    Foreword
    Jon Wigginton
    Jon Wigginton
    Chief Medical Officer, Cullinan Oncology
    Jon Wigginton, MD currently serves as portfolio Chief Medical Officer, Cullinan Oncology and Advisor at MPM Capital. Dr. Wigginton most recently served as the Chief Medical Officer at MacroGenics, where he led the company's evolution of a fully-integrated, clinical-stage cancer immunotherapy organization. Previously, he served as the Therapeutic Area Head, Immuno-Oncology, Early Clinical Research at Bristol-Myers Squibb. There, he oversaw early clinical development of the BMS Immuno-Oncology portfolio, served in governance role for discovery research, and co-led the BMS International Immuno-Oncology Network (II-ON). These efforts included several studies defining proof-of concept for both anti-PD-1 and anti-PD-L1 antibodies in patients with a variety of solid tumors, and for the anti-PD-1/anti-CTLA-4 combination in patients with melanoma. During his academic career, Dr. Wigginton served as Head of the Investigational Biologics Section, Center for Cancer Research, NCI, where he led an integrated basic, translational and clinical research effort focused on combination immunotherapy in preclinical models and early clinical studies. Dr. Wigginton also served previously as president of the Society for Immunotherapy of Cancer (SITC). Dr. Wigginton received his M.D. and B.S. in Biology, with distinction, from the University of Michigan.
  • Analyzing current trends and future directions in I-O clinical development

    Analyzing current trends and future directions in I-O clinical development

    14 September 2020
    Interview
    Daina Graybosch
    Daina Graybosch
    Managing Director, Immuno-Oncology, SVB Leerink
  • Expert Roundtable: Clinical success of checkpoint inhibitors: what's next for combination therapy in I-O?

    Expert Roundtable: Clinical success of checkpoint inhibitors: what's next for combination therapy in I-O?

    8 October 2020
    Expert Roundtable Video
    Jason J Luke,
    Jason J Luke
    Associate Professor of Medicine, University of Pittsburgh Medical Center; Director of Cancer Immunotherapeutics, Hillman Cancer Center
    Justin Fairchild ,
    Justin Fairchild
    Vice President of Clinical Development, Parker Institute for Cancer Immunotherapy
    Robin G. Taylor,
    Robin G. Taylor
    Independent Biopharma Strategy Consultant
    Reni J. Benjamin
    Reni J. Benjamin
    Managing Director, Equity Research, Biotechnology, JMP Securities
  • Expert Roundtable: Clinical success of checkpoint inhibitors: what's next for combination therapy in I-O?

    Expert Roundtable: Clinical success of checkpoint inhibitors: what's next for combination therapy in I-O?

    11 November 2020
    Expert Roundtable
    Jason J Luke,
    Jason J Luke
    Associate Professor of Medicine, University of Pittsburgh Medical Center; Director of Cancer Immunotherapeutics, Hillman Cancer Center
    Justin Fairchild ,
    Justin Fairchild
    Vice President of Clinical Development, Parker Institute for Cancer Immunotherapy
    Robin G. Taylor,
    Robin G. Taylor
    Independent Biopharma Strategy Consultant
    Reni J. Benjamin
    Reni J. Benjamin
    Managing Director, Equity Research, Biotechnology, JMP Securities
  • Clinical development strategy of immunotherapy combination

    T Enokida,
    Tomohiro Enokida
    Department of Medicine, Precision Immunology Institute, Tisch Cancer Institute
    C Carr,
    Caitlin Carr
    Department of Medicine, Precision Immunology Institute, Tisch Cancer Institute
    N Bhardwaj
    Nina Bhardwaj
    Department of Medicine, Precision Immunology Institute
    10 December 2020
    Expert Insight
  • Expert Roundtable: Clinical success of checkpoint inhibitors: what's next for combination therapy in I-O?

    J Luke,
    Jason J Luke
    Associate Professor of Medicine, University of Pittsburgh Medical Center; Director of Cancer Immunotherapeutics, Hillman Cancer Center
    J Fairchild ,
    Justin Fairchild
    Vice President of Clinical Development, Parker Institute for Cancer Immunotherapy
    R Taylor et al.
    Robin G. Taylor
    Independent Biopharma Strategy Consultant
    11 November 2020
    Expert Roundtable
  • The concept of ‘iatrogenic resistance’: insights into mechanisms of induction of resistance to immune checkpoint blockade in combination immunotherapy

    S Gupta,
    Seema Gupta
    The Loop Immuno-Oncology Laboratory, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center
    S Khleif
    Samir N Khleif
    The Loop Immuno-Oncology Laboratory, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center
    8 October 2020
    Commentary
  • Analyzing current trends and future directions in I-O clinical development - Podcast

    D Graybosch
    Daina Graybosch
    Managing Director, Immuno-Oncology, SVB Leerink
    8 October 2020
    Podcast
  • Cancer Immunotherapy 2020: Opportunities and Challenges on the Road Ahead

    F Arnaldez,
    Fernanda Arnaldez
    Executive Medical Director, Global Clinical Development at MacroGenics, Inc.
    J Wigginton
    Jon Wigginton
    Chief Medical Officer, Cullinan Oncology; Advisor, MPM Capital
    Jon Wigginton, MD currently serves as portfolio Chief Medical Officer, Cullinan Oncology and Advisor at MPM Capital. Dr. Wigginton most recently served as the Chief Medical Officer at MacroGenics, where he led the company's evolution of a fully-integrated, clinical-stage cancer immunotherapy organization. Previously, he served as the Therapeutic Area Head, Immuno-Oncology, Early Clinical Research at Bristol-Myers Squibb. There, he oversaw early clinical development of the BMS Immuno-Oncology portfolio, served in governance role for discovery research, and co-led the BMS International Immuno-Oncology Network (II-ON). These efforts included several studies defining proof-of concept for both anti-PD-1 and anti-PD-L1 antibodies in patients with a variety of solid tumors, and for the anti-PD-1/anti-CTLA-4 combination in patients with melanoma. During his academic career, Dr. Wigginton served as Head of the Investigational Biologics Section, Center for Cancer Research, NCI, where he led an integrated basic, translational and clinical research effort focused on combination immunotherapy in preclinical models and early clinical studies. Dr. Wigginton also served previously as president of the Society for Immunotherapy of Cancer (SITC). Dr. Wigginton received his M.D. and B.S. in Biology, with distinction, from the University of Michigan.
    8 October 2020
    Commentary
  • Expert Roundtable: Clinical success of checkpoint inhibitors: what's next for combination therapy in I-O?

    J Luke,
    Jason J Luke
    Associate Professor of Medicine, University of Pittsburgh Medical Center; Director of Cancer Immunotherapeutics, Hillman Cancer Center
    J Fairchild ,
    Justin Fairchild
    Vice President of Clinical Development, Parker Institute for Cancer Immunotherapy
    R Taylor et al.
    Robin G. Taylor
    Independent Biopharma Strategy Consultant
    8 October 2020
    Expert Roundtable Video
  • Finding the white space: a multi-stakeholder approach to accelerating combination drug development

    J O’Donnell-Tormey
    Jill O’Donnell-Tormey
    Chief Executive Officer and Director of Scientific Affairs of the Cancer Research Institute (CRI)
    18 September 2020
    Interview
  • How will the rapidly developing I-O combination therapy picture continue to evolve?

    R Baynes
    Roy Baynes
    Senior Vice President, Global Clinical Development at Merck & Co, Inc
    Roy D Baynes is Senior Vice President Global Clinical Development and Chief Medical Officer at Merck Research Laboratories in Rahway, New Jersey. He was previously Senior Vice President of Oncology, Inflammation and Respiratory Therapeutics at Gilead Sciences and prior to that was Vice President Global Clinical Development and Therapeutic Area (TA) Head for Hematology/Oncology, at Amgen Inc. In the early years of his tenure at Amgen before becoming TA head of Hematology/Oncology in Clinical Development he was TA head for Hematology/Oncology in Global Medical Affairs. He graduated as a Medical Doctor and obtained a Master of Medicine and Doctor of Philosophy from the University of the Witwatersrand, Johannesburg, South Africa. He has had a long and distinguished career in the hematology-oncology-and stem cell transplantation fields, including drug development, basic research, clinical practice, clinical research, teaching and administration. He is a member of many international societies, including the American Society of Hematology (ASH) and the American Society of Clinical Oncology (ASCO), and has authored some 150 publications. He has been recurrently named among America’s top physicians. Before joining Amgen in 2002, he was the Charles Martin Professor of Cancer Research at the Barbara Ann Karmanos Cancer Institute, an NCI designated Comprehensive Cancer Center, at Wayne State University, Detroit, Michigan, USA.
    16 September 2020
    Interview
  • Analyzing current trends and future directions in I-O clinical development

    D Graybosch
    Daina Graybosch
    Managing Director, Immuno-Oncology, SVB Leerink
    14 September 2020
    Interview
  • Immuno-Oncology Insights - Spotlight on clinical development strategy

    J Wigginton
    Jon Wigginton
    Chief Medical Officer, Cullinan Oncology
    Jon Wigginton, MD currently serves as portfolio Chief Medical Officer, Cullinan Oncology and Advisor at MPM Capital. Dr. Wigginton most recently served as the Chief Medical Officer at MacroGenics, where he led the company's evolution of a fully-integrated, clinical-stage cancer immunotherapy organization. Previously, he served as the Therapeutic Area Head, Immuno-Oncology, Early Clinical Research at Bristol-Myers Squibb. There, he oversaw early clinical development of the BMS Immuno-Oncology portfolio, served in governance role for discovery research, and co-led the BMS International Immuno-Oncology Network (II-ON). These efforts included several studies defining proof-of concept for both anti-PD-1 and anti-PD-L1 antibodies in patients with a variety of solid tumors, and for the anti-PD-1/anti-CTLA-4 combination in patients with melanoma. During his academic career, Dr. Wigginton served as Head of the Investigational Biologics Section, Center for Cancer Research, NCI, where he led an integrated basic, translational and clinical research effort focused on combination immunotherapy in preclinical models and early clinical studies. Dr. Wigginton also served previously as president of the Society for Immunotherapy of Cancer (SITC). Dr. Wigginton received his M.D. and B.S. in Biology, with distinction, from the University of Michigan.
    9 September 2020
    Foreword